🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · Real-Time Price · USD
0.1944
-0.0357 (-15.51%)
At close: Nov 18, 2026, 4:00 PM EST
0.1944
0.00 (0.00%)
Pre-market: Nov 19, 2026, 7:20 AM EST

Acumen Pharmaceuticals Stock Forecast

ABOS's stock price has decreased by -87.7% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 6 analysts with 12-month price forecasts for Acumen Pharmaceuticals stock have an average target of $1.00, which predicts a 414.40% increase from the current stock price of 0.19.

Price Target: $1.00 (+414.40%)
Analyst Consensus: Hold

Price Target

Chart
TargetLowAverageMedianHigh
Price$1.00$1.00$1.00$1.00
Change+414.40%+414.40%+414.40%+414.40%

Analyst Ratings

The average analyst rating for Acumen Pharmaceuticals stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.

Recommendation Trends

Chart
RatingJun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Strong Buy666611
Buy000000
Hold000033
Sell000011
Strong Sell000011
Total666666

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Lucid Capital
Lucid Capital
Hold
Downgrades
$7 → $1
HoldDowngrades$7 → $1+414.40%Nov 2, 2026
BTIG
BTIG
Buy
Maintains
$8 → $1
BuyMaintains$8 → $1+414.40%Nov 2, 2026
Citi
Citi
Hold
Downgrades
$5 → $1
HoldDowngrades$5 → $1+414.40%Nov 2, 2026
Cantor Fitzgerald
Cantor Fitzgerald
Sell
Downgrades
n/a
SellDowngradesn/an/aOct 30, 2026
Bank of America Securities
Bank of America Securities
Sell
Downgrades
$8 → $1
SellDowngrades$8 → $1+414.40%Oct 30, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.61
from -2.00
EPS Next Year
-0.49
from -1.61
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
------
Operating Income
-19.58M-45.24M-61.14M-114.02M-123.83M-107.95M
Net Income
-100.61M-42.86M-52.37M-102.33M-121.34M-106.08M
EPS
-----2.00-1.61
Free Cash Flow
-----115.63M-89.00M
No. Analysts
-----4
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
Highn/a
Avgn/a
Lown/a

Revenue Growth

Revenue Growth20272028
High-
Avg-
Low-

EPS Forecast

EPS202620272028
High-1.50
Avg-1.61
Low-1.72

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-